美股A股
StockGist
Back to GKOS
Q2 20262026-07-29· deepseek:deepseek-v4-flash

GKOS earnings call summary

Prepared Highlights

Prepared Metrics

MetricValueSpeaker/Context
2026Q2 consolidated net sales$185.6 million;YoY +50% reported / +49% constant currencyCEO
U.S. glaucoma franchise net sales$118.5 million;YoY +64%CEO
iDose TR sales约 $74 millionCEO
International glaucoma net sales$36.6 million;YoY +17% reported / +16% constant currencyCEO
Corneal Health net sales$30.4 million;YoY +48%CEO
Epioxa sales约 $11 millionCEO
FY2026 net sales guidance$680 million–$700 millionCEO
Prior FY2026 net sales guidance$620 million–$635 millionCEO

Mgmt Quotes

Q&A Batch (1-5 of 12)

Q1 — Thomas Stephan

Q2 — Adam Maeder

Q3 — Larry Biegelsen

Q4 — Ryan Zimmerman

Q5 — K. Gong

Q&A Batch (6-10 of 12)

Q6 — Richard Newitter

Q7 — Joanne Wuensch

Q8 — Mason Carrico

Q9 — David Saxon

Q10 — Steven Lichtman

Q&A Batch (11-12 of 12)

Q11 — Anthony Petrone

Q12 — Katherine Degen(代 Yi)